Clopidogrel
Product Images NDC 53808-1025

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 53808-1025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula For Clopidogrel Bisulfate (90c2699c Bee5 48a3 Bfda 478d66c5a261 01)

Chemical structure of Clopidogrel bisulfate depicting the molecular configuration including a thiophene ring, chloro-substituted phenyl group, and ester functional group bound to a bisulfate molecule.*

FDA Label Image

Figure 1 (90c2699c Bee5 48a3 Bfda 478d66c5a261 02)

A horizontal error bar chart illustrating the effect of coadministered proton pump inhibitors (PPIs) at specified doses on the active metabolite AUC of clopidogrel. The chart compares changes relative to clopidogrel alone for dex lansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg, showing mean values with 90% confidence intervals.*

FDA Label Image

Figure 2 (90c2699c Bee5 48a3 Bfda 478d66c5a261 03)

A line graph depicting cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up, comparing Clopidogrel (+ aspirin) and Placebo (+ aspirin) treatment groups. The y-axis shows cumulative event rate percentages from 0 to 16%, and the x-axis shows months of follow-up from 0 to 12. Statistical significance is noted with P = 0.00009.*

FDA Label Image

Figure 3 (90c2699c Bee5 48a3 Bfda 478d66c5a261 04)

A forest plot chart titled 'Percent Events' comparing the hazard ratio of Clopidogrel versus placebo across various subgroups based on characteristics such as diagnosis, age, gender, race, medical history, and concomitant medication or therapy. Horizontal lines with markers represent the confidence intervals and hazard ratios, illustrating which treatment performed better within each subgroup.*

FDA Label Image

Figure 3: Cumulative Event Rates For Death In The Commit Study (90c2699c Bee5 48a3 Bfda 478d66c5a261 05)

A Kaplan-Meier survival curve comparing the percentage of deaths before first discharge over 28 days between Clopidogrel and placebo groups. The graph shows deaths (%) on the vertical axis and days since randomization on the horizontal axis, with associated death counts and a noted 7% proportional risk reduction (p=0.03) for Clopidogrel versus placebo.*

FDA Label Image

Figure 5 (90c2699c Bee5 48a3 Bfda 478d66c5a261 06)

A Kaplan-Meier curve showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. The graph compares two groups: placebo (10.1% event rate) and Clopidogrel (9.2% event rate), with a reported 9% proportional risk reduction (p=0.002). The x-axis represents days since randomization, and the y-axis represents the percentage with events.*

FDA Label Image

Figure 6 (90c2699c Bee5 48a3 Bfda 478d66c5a261 07)

A forest plot chart showing event percentages for Clopidogrel versus placebo across various baseline categories such as sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation. The chart includes odds ratios with confidence intervals and heterogeneity test results, illustrating comparative treatment effect and statistical significance.*

FDA Label Image

Figure 7 (90c2699c Bee5 48a3 Bfda 478d66c5a261 08)

A forest plot comparing event percentages between Clopidogrel and Placebo groups across subcategories such as Killip class, previous myocardial infarction (MI), and infarct location. The plot shows odds ratios with confidence intervals indicating proportional reduction in events for Clopidogrel compared to Placebo, along with heterogeneity and trend test p-values.*

FDA Label Image

Figure 8 (90c2699c Bee5 48a3 Bfda 478d66c5a261 09)

A line graph comparing fatal or non-fatal vascular event rates over 36 months of follow-up for two treatments: Clopidogrel and Aspirin. The y-axis shows cumulative event rate in percent, ranging from 0 to 16, while the x-axis shows months of follow-up from 0 to 36. The graph indicates a statistically significant difference with a P-value of 0.045.*

FDA Label Image

Label Image For 75mg (Clopidogrel 75mg)

Label for Clopidogrel 75 mg tablets, quantity 30, labeled by State of Florida DOH Central Pharmacy in Tallahassee, FL. Includes lot number, expiration date 07-24-2014, and barcode. The label specifies RX Only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.